Biotechnology Law Report

Papers
(The median citation count of Biotechnology Law Report is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
CareDx, Inc. v. Natera, Inc. United States Court of Appeals of the Federal Circuit, 2022 40 F.4th 137114
The Localization of Drug Patent Linkage System in China: Where Should It Go?4
Legal Governance of Human Gene Editing Technology: From Single Governance to Multiple Governance3
To What Extent Does Mayo v. Prometheus Allow for the Patenting of Diagnostic Methods?3
Trade Secret Protection on a Publicly Sold, Patented Spinal Implant Device: Life Spine, Inc. v. Aegis Spine, Inc.3
Patents Cannot Be Blamed for Inequitable Access to COVID-19 Vaccines3
Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies2
Selected Developments in Biotechnology Law and the Biotechnology Industry2
Supplementary Protection Certificates in Europe: Clarity at Last?2
Sanho Corp. v. Kaijet Tech. Int’l Ltd., Inc1
An Innovation Principle in Gene Technology Law?1
Landscape of Genome Editing Technology Patents in the European Patent Office with a Focus on CRISPR-Related Opposition Proceedings1
The Evolving Grace Period for U.S. Patent Applicants1
Natera, Inc. v. NeoGenomics Lab’ys, Inc1
Univ. of S. Fla. Bd. of Trustees v. United States1
Recent Developments in FDA Regulatory Exclusivities1
Salix Pharms., Ltd. v. Norwich Pharms. Inc.1
Biotechnology and Intellectual Property Law: Theoretical and Practical Reflections on Albanian National Law and Jurisprudence in Comparison with EU Acquis and ECJ Case Law1
Univ. of Massachusetts v. L'Oreal S.A.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Legal and Ethical Challenges in the Construction of China's Biobanks1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
14-Day Limit of Human Embryo Research: Moral Issues in the Patent Law in China1
Mylan Pharms. Inc. v. Merck Sharp & Dohme Corp. United States Court of Appeals of the Federal Circuit, 2022 50 F.4th 1471
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
In re Huping Hu: Quantum Entanglement, Medical Innovation, and Patentability on the Scientific “Fringe”1
Observation on China's Performance in the Global Supply Chain of COVID-19 Medicine1
ChromaDex, Inc. v. Elysium Health, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 12801
Federal Circuit Reiterates That Drug Safety and Efficacy Are Issues for the FDA, Not the Patent Laws1
The Redemption of Drug Patent Linkage System: The Dilemma and Improvement in the Qualification System of Market Exclusivity Period for China’s First Generic Drug1
Bio-Rad Lab'ys, Inc. v. Int'l Trade Comm'n1
Allgenesis Biotherapeutics Inc. v. Cloudbreak Therapeutics, LLC1
A 12th Year 101 Update—Diagnostic and DNA Claims Are Patent Eligible, but Pre-Mayo Patents May Continue to Fall1
A Review of Patent Regimes on Health Biotechnology Innovation in India1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
Dilemma and Solution of Intellectual Property Protection of Biological Genetic Resources1
Nippon Shinyaku Co. v. Sarepta Therapeutics, Inc.1
United Therapeutics Corp. v. Liquidia Techs., Inc.1
Astellas Pharma, Inc. v. Sandoz Inc. USA, Inc.1
AstraZeneca AB v. Mylan Pharms. Inc.1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
In re Entresto1
Selected Developments in Biotechnology Law and the Biotechnology Industry1
ModernaTx, Inc. v. Arbutus Biopharma Corp.1
Pac. Biosciences of California, Inc. v. Pers. Genomics Taiwan, Inc1
China's Challenges in Implementing Compulsory Drug Patent Licenses and its Response in the Context of COVID-191
Research on the Latest Progress of “Mechanism for Early Resolution of Patent Disputes” for Biological Products in China1
Hologic, Inc. v. Minerva Surgical, Inc.1
Moo-re Gene-edited Animals Get Regulatory Clearance: U.S. FDA Approves Genetically Engineered Cattle for Human Consumption1
Tris Pharma, Inc. v. Actavis Lab'ys FL, Inc.1
Minerva Surgical, Inc. v. Hologic, Inc.0
Unproven Stem Cell Industry in the U.S.: Regulatory Challenges and Enforcement Issues0
Takeda Pharm. Co. Ltd. v. Torrent Pharm. Ltd. United States Court of Appeals of the Federal Circuit, 2021 No. 2020-1552, 2021 WL 560763 (nonprecedential)0
Cytiva BioProcess R&D AB v. JSR Corp.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Amgen Inc. v. Sanofi, Aventisub LLC United States Court of Appeals of the Federal Circuit, 2021 987 F.3d 10800
Jazz Pharms., Inc. v. Avadel CNS Pharms., LLC United States Court of Appeals of the Federal Circuit, 2023 No. 2023-1186, 2023 WL 21986400
Recent Developments in the Listing of Patents in FDA's Orange Book0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Ethical Boundary of the Development of Human Gene Editing Technology0
In re Couvaras0
The Drawing-Up of Laws on Research Involving Human Embryos in Australia: Lack of an Islamic Voice0
Recent Developments at the Intersection of Pharma, Patents, and Antitrust Law0
Amarin Pharma, Inc. v. Hikma Pharms. USA, Inc.0
Minerva Surgical, Inc. v. Hologic, Inc. United States Court of Appeals of the Federal Circuit, 2023 59 F.4th 13710
Selected Developments in Biotechnology Law and the Biotechnology Industry0
In Minerva v. Hologic, the U.S. Supreme Court Reins in the Equitable Doctrine of Assignor Estoppel0
Navigating Procedural Challenges in Biotechnological Patenting: A Path Forward for India’s Innovation Landscape0
Cornell Rsch. Found., Inc. v. Vidal0
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I0
The Federal Circuit Continues to Grapple with the Question of Patent Eligibility for Diagnostic Methods0
The EPO Guidelines They Are a-Changin’0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Juno Therapeutics, Inc. v. Kite Pharma, Inc. United States Court of Appeals of the Federal Circuit, 202110 F.4th 13300
A Crisis on Patenting of “Ready-to-Use” Oral Liquid Formulations: Azurity Pharms., Inc. v. Alkem Lab’ys Ltd0
How a Dosage Regimen Patent for RRMS Treatment May Satisfy the Written Description Requirement—A Lesson from Novartis Pharmaceuticals Corp. v. Accord Healthcare, Inc.0
The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRIPSR0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Regulation of Biomedical Research: Global and Indian Perspective0
Regeneron Pharms., Inc. v. Mylan Pharms. Inc.0
Regulatory Landscape for Generic Drugs in India: Assessing Quality, Safety, and Efficacy Standards0
Edwards Lifesciences Corp. v. Meril Life Scis. Pvt. Ltd0
Actelion Pharms. LTD v. Mylan Pharms. Inc.0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Galderma Lab’ys, L.P. v. Lupin Inc0
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part II0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
In re Huping Hu United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2104, 2021 WL 1016437 (non-precedential)0
Innovate, Evaluate, Legislate: U.S. Senators Forge a Path to Assess Artificial Intelligence’s Biosecurity Quandary0
In Juno v. Kite the Federal Circuit Strikes Down Patent Directed Towards Pioneering Innovation in CAR T-Cell Therapy0
Univ. of S. Fla. Bd. of Trustees v. United States and the Federal Government’s Nonexclusive License under the Bayh-Dole Act0
The Enablement and Written Description Requirements Through the Lens of the Federal Circuit's Actions (As Opposed to Its Words)0
Genentech, Inc. v. Sandoz, Inc.0
A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
The U.S. Patent and Trademark Office Proposes New Rules Targeting Continuation Practice and Terminal Disclaimers0
Sanofi-Aventis Deutschland GmbH v. Mylan Pharms. Inc.0
Gilead Scis., Inc. v. United States0
Teva Branded Pharmaceutical Products R&D, Inc. v. Amneal Pharmaceuticals of New York, LLC0
The U.S. Patent and Trademark Office’s Response to Recent Developments in Artificial Intelligence0
Correction to: AI (Re)Defining Pharmaceutical Exclusivities, by Jonathan Kimball and Srividhya Ragavan, Biotechnol Law Rep 2022;41(1):23–29; doi: 10.1089/blr.2021.29257.sr0
Celanese Int’l Corp. v. Int’l Trade Comm’n0
Regulation of Clinical Trials and Pandemic Research: Upholding Ethical Standards During a COVID-19 Crisis0
Novartis Pharms. Corp. v. Accord Healthcare, Inc.0
Novartis Pharms. Corp. v. Accord Healthcare, Inc.0
Amgen Inc. v. Sandoz Inc. United States Court of Appeals of the Federal Circuit, 2023 No. 2022-1147, 2023 WL 29941660
The Fate of FTC v. Actavis, Inc. in the Biosimilar Context—Does and Should the FTC v. Actavis Decision Apply to Reverse Patent Settlements Between Brand Drug and Biosimilar Manufacturers0
In re Bd. of Trustees of Leland Stanford Junior Univ. United States Court of Appeals of the Federal Circuit, 2021 No. 2020-1012, 2021 WL 9227270
Purdue Pharma L.P. v. Collegium Pharm., Inc0
Allergan USA, Inc. v. MSN Lab’ys Priv. Ltd0
Janssen Pharms., Inc. v. Teva Pharms. USA, Inc0
The Legal Protection of Gene Private Rights0
A Feasible Pathway for Open Access to Human Embryonic Stem Cell Patents—With China's Open License for Patent as the Entry Point0
A 2023 Review of Legislation Aimed at Increasing Generic and Biosimilar Competition0
AI (Re)Defining Pharmaceutical Exclusivities0
HIPAA, HIPPA, or HIPPO: What Really Is the Heath Insurance Portability and Accountability Act?0
Pfizer Inc. v. Sanofi Pasteur Inc0
GlaxoSmithKline II and Other Recent Developments in Induced and Contributory Patent Infringement0
Observation on the R&D Effectiveness and Application of China's Novel Coronavirus Vaccine0
Taiwan's Efforts to Recreate Remdesivir0
In re Entresto and the Standard of Review for Compliance with the Written Description Requirement0
Pac. Biosciences of California, Inc. v. Oxford Nanopore Techs., Inc. United States Court of Appeals of the Federal Circuit, 2021 996 F.3d 1340
GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.United States Court of Appeals of the Federal Circuit, 20217 F.4th 13200
Patentability Analysis of “Intelligent” Disease Diagnosis Methods in China in the Era of Smart Health Care0
Balancing Innovation and Biomedical Ethics within National Institutes of Health: Integrative and Regulatory Reforms for Artificial Intelligence-Driven Biotechnology0
Pleading Use of Trade Secrets Concerning a Biological Product by Showing Product-Related Similarities: Allergan, Inc. v. Revance Therapeutics, Inc.0
Rosalind Franklin Society Proudly Announces the 2023 Award Recipient for Biotechnology Law Report0
Review of the UK's R&D Tax Reliefs—A Good News Story for the UK's Life Sciences Sector?0
Legal Perspective of Genetically Modified Crops and Drowsy Stance of International Actors0
H. Lundbeck A/S v. Lupin Ltd.0
Teva v. Amneal: The Federal Circuit Weighs in on the Listing of Patents Relating to Drug-Device Combinations in the Orange Book0
Janssen Ortho, LLC v. United States0
ModernaTx, Inc. v. Arbutus Biopharma Corp.0
China Releases Document on Ethics Review of Life Sciences: Comments and Compliance Guidelines0
Par Pharm., Inc. v. Eagle Pharms., Inc.0
A Pharmaceutical Formulation as a Claim Term Cannot “Target” a Plasma Concentration-Time Profile Under 35 U.S.C. § 112: A Lesson from Horizon Pharma, Inc. v. Dr. Reddy's Laboratories Inc.0
How Science, Technology, and Society Influence Patent Policies: The Choice and Direction of Gene Patent Pathways from the View of Technoscience0
SawStop Holding LLC v. Vidal United States Court of Appeals of the Federal Circuit, 2022 48 F.4th 13550
Trustees of Columbia Univ. in City of New York v. Illumina, Inc. United States Court of Appeals of the Federal Circuit, 2021 No. 2019-2302, 2021 WL 317661 (nonprecedential)0
Challenges in Patenting Human Stem Cell Inventions: A Comparative Perspective in USA, Europe, and India—Is India Lagging?0
Navigating Cross-Border Challenges In Biobanking: Analysing Eu Legislation, ECJ Case Law, and the Role of Private International Law0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Japanese CRISPR Patent and Biotech Developments in the Early Reiwa Era0
Rosalind Franklin Society Proudly Announces the 2022 Award Recipient for Biotechnology Law Report0
Observation on the Admission Situation of the Anti-Coronavirus Drug “Remdesivir” in China0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
UCB, Inc. v. Actavis Lab'ys UT, Inc.0
Research on Intellectual Property Right Protection of Genetic Resources in China Under Benefit-Sharing0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
A Review of Judicial Opinions Interpreting the Novelty Provisions of the America Invents Act0
Selected Developments in Biotechnology Law and the Biotechnology Industry0
Bayer Healthcare LLC v. Baxalta Inc. United States Court of Appeals of the Federal Circuit, 2021 989 F.3d 9640
Arbutus Biopharma Corp. v. ModernaTX, Inc. United States Court of Appeals of the Federal Circuit, 2023 65 F.4th 6560
Medytox, Inc. v. Galderma S.A.0
The Legislative Paradigm of China's Biosafety Law and Its Positive Significance for the SARS-CoV-2 Prevention and Control0
0.089664936065674